EP
BIIB icon

Eversept Partners’s Biogen BIIB Stock Holding History

Eversept Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,100
Closed -$9.91M – 70
2022
Q3 		$9.91M Buy
+37,100
New +$7.88M 0.86% 25
2022
Q2 		– Sell
-140,000
Closed -$29.5M – 83
2022
Q1 		$29.5M Buy
+140,000
New +$30.4M 2.26% 17
2021
Q3 		– Sell
-115,600
Closed -$40M – 108
2021
Q2 		$40M Buy
+115,600
New +$35M 2.67% 12

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Eversept Partners's BIIB Position: Q1 2026 in Review

Eversept Partners sold out of Biogen (BIIB) in Q1 2026, closing a stake of 77,944 shares — an estimated $13.7M sold.

Eversept Partners first reported a position in BIIB in Q4 2021 and held it in 8 quarters. The position peaked at $42.8M in Q1 2023. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Eversept Partners reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Eversept Partners sold 77,944 Biogen shares in Q1 2026, an estimated $13.7M.
  • Eversept Partners first reported a position in Biogen in Q4 2021 and held it in 8 quarters.
  • Eversept Partners's Biogen position peaked at $42.8M in Q1 2023.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.